New Blood Test Shows 96% Accuracy in Diagnosing Chronic Fatigue Syndrome

Scientists in the United Kingdom have developed a blood test capable of diagnosing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) with 96 percent accuracy, offering a potential solution to the long-standing challenge of identifying the debilitating condition.

Currently, diagnosis relies on a patient experiencing disabling fatigue for at least six months, alongside post-exertional malaise, and ruling out other conditions with similar symptoms – a process that can take years. This new test identifies biomarkers related to epigenetic changes, alterations in chromosome structure influenced by factors like stress and infection, creating a unique biological “signature” in individuals with ME/CFS. The study, a proof-of-concept, demonstrated 92 percent sensitivity and 98 percent specificity in identifying the condition.

Researchers examined blood samples from 47 participants with severe ME/CFS and 61 healthy controls, identifying approximately 200 biomarkers. While promising, the study acknowledges limitations, including a relatively small sample size and a participant group with more females and severely affected, housebound individuals. Further research is needed to determine how factors like sex and activity levels influence the biomarkers and to validate the test’s accuracy across diverse populations and against other conditions with overlapping symptoms, such as fibromyalgia. Early and accurate diagnosis is crucial, as evidence suggests early intervention, like rest during the initial stages of illness, can improve long-term outcomes, mirroring findings in long COVID.

Researchers are now focused on validating these biomarkers in larger, more diverse groups and ensuring any resulting test is affordable and accessible to all who need it.